What is HC Wainwright’s Forecast for TSE:ONC Q1 Earnings?

Oncolytics Biotech Inc. (TSE:ONC) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Oncolytics Biotech in a research note issued on Friday, April 10th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.03) EPS and FY2030 earnings at $0.25 EPS.

Oncolytics Biotech Trading Down 1.3%

TSE:ONC opened at C$14.90 on Monday. Oncolytics Biotech has a 12 month low of C$0.44 and a 12 month high of C$2.08. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The company’s 50 day moving average is C$14.90 and its 200-day moving average is C$14.90.

Insider Buying and Selling

In other news, insider Andrew P. Aromando purchased 29,600 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were bought at an average price of C$1.18 per share, with a total value of C$34,928.00. Following the completion of the transaction, the insider directly owned 55,100 shares in the company, valued at C$65,018. This trade represents a 116.08% increase in their position. Also, Director Bernd Robert Seizinger purchased 60,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was purchased at an average cost of C$1.14 per share, for a total transaction of C$68,400.00. Following the transaction, the director owned 526,991 shares of the company’s stock, valued at approximately C$600,769.74. This trade represents a 12.85% increase in their ownership of the stock. Over the last 90 days, insiders have purchased 289,232 shares of company stock valued at $335,760. 3.82% of the stock is owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.